Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I/II Study of AZD1222 (Vaxzevria) for COVID-19 Prevention in Japan
NCT04568031Phase 2Completed
- Sponsor
- AstraZeneca
- Start
- Aug 2020
- Primary completion
- Nov 2021
- Modality
- Viral Vector Vaccines
- Countries
- 1
01
Overview
A Phase 2 trial of ChAdOx1 nCoV-19 in coronavirus disease 2019 (COVID-19), sponsored by AstraZeneca. Started Aug 2020; status: completed.
02
Drugs
ChAdOx1 nCoV-19
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04568031.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04568031.